3589-41-1

Usage

Uses

Used in Pharmaceutical Synthesis:
N-CARBOBENZOXYAMINOACETONITRILE is used as an intermediate in the synthesis of various pharmaceutical compounds, playing a crucial role in the development of new medications.
Used as a Protecting Group in Organic Synthesis:
In organic synthesis, N-CARBOBENZOXYAMINOACETONITRILE is utilized as a protecting group for the amino group, allowing for selective reactions to proceed without affecting other functional groups present in the molecule.
Used in the Production of Derivatives:
N-CARBOBENZOXYAMINOACETONITRILE is also used in the production of peptide, ester, and amine derivatives, contributing to the structural diversity and functional properties of these chemical entities.
Used in Drug Design and Development:
N-CARBOBENZOXYAMINOACETONITRILE has been studied for its potential applications in the design and development of new drugs for various medical conditions, indicating its importance in medicinal chemistry and pharmaceutical research.

InChI:InChI=1/C10H10N2O2/c11-6-7-12-10(13)14-8-9-4-2-1-3-5-9/h1-5H,7-8H2,(H,12,13)

Upstream product

• 126714-85-0 2,3-dichlorothiophene-5-sulfonyl chloride 
• 6011-14-9 2-aminoacetonitrile hydrochloride 
• 501-53-1 benzyl chloroformate 
• 151-63-3 aminoacetonitrile neutral sulfate 
• 75315-63-8 N-(benzyloxycarbonyl)succinimide 
• 151-63-3 cyanomethylamine sulfate 
• 1885-14-9 phenyl chloroformate 
• 55378-79-5 C₁₃H₁₅NO₆ 
• 1138-80-3 N-(Benzyloxycarbonyl)glycine 
• 949-90-6 N-(carbobenzyloxy)glycinamide 
• 125453-11-4 benzyl N-(1H-benzotriazol-1-ylmethyl)carbamate 
• 540-61-4 2-aminoacetonitrile 

Downstream Products

• 949-90-6 N-(carbobenzyloxy)glycinamide 
• 49548-40-5 N-benzyloxycarbonylglycine thioamide 
• 51030-44-5 ethyl 2-benzyloxycarbonylaminoacetimidate hydrochloride 
• 859918-98-2 2-benzyloxycarbonylamino-acetimidic acid cyclohexyl ester 
• 101724-49-6 2-amino-acetimidic acid cyclohexyl ester; dihydrobromide 
• 117087-85-1 2-Benzyloxycarbonylamino-acetimidic acid methyl ester; hydrochloride 
• 117087-86-2 2-Benzyloxycarbonylamino-acetimidic acid 2-nitro-ethyl ester; hydrochloride 
• 140903-15-7 (Benzyloxycarbonylamino)thioacetimidsaeure-propylester hydrochlorid 
• 18877-94-6 ethyl 2-phenylmethoxycarbonylaminoethaneimidothioate monohydrochloride 
• 1146897-13-3 C₂₁H₂₆N₂O₄ 
• 1146897-17-7 C₂₀H₂₈N₂O₃Si 
• 1146897-15-5 C₂₀H₂₄N₂O₄ 
• 1257340-94-5 C₁₉H₁₆F₃N₃O₃ 
• 367939-83-1 (E)-2-Penylethyl-N-(benzyloxycarbonyl)glycinhydroximat 

Relevant academic research and scientific papers

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Preparation method and intermediate of benzodiazepine compound

The invention discloses a preparation method of a benzodiazepine compound and an intermediate compound K. The compound K disclosed by the invention can be used for preparing the compound shown as theformula I in one step at high yield. The preparation met

Acceptor-Controlled Transfer Dehydration of Amides to Nitriles

Palladium-catalyzed dehydration of primary amides to nitriles efficiently proceeds under mild, aqueous conditions via the use of dichloroacetonitrile as a water acceptor. A key to the design of this transfer dehydration catalysis is the identification of an efficient water acceptor, dichloroacetonitrile, that preferentially reacts with amides over other polar functional groups with the aid of the Pd catalyst and makes the desired scheme exergonic, thereby driving the dehydration.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS

The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

HETEROCYCLIC COMPOUNDS AND USE THEREOF

Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation, and for treating tissue injury, cancer, inflammatory disease, and autoimmune disease.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.